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Abstract
Background: Differentiated thyroid carcinoma offers a good model to investigate the possible correlation between
specific gene mutations and chromosome instability. Papillary thyroid neoplasms are characterized by different
mutually exclusive genetic alterations, some of which are associated with aneuploidy and aggressive phenotype.
Results: We investigated the centrosome status and mitotic abnormalities in three thyroid carcinoma-derived cell
lines, each maintaining the specific, biologically relevant gene alteration harbored by the parental tumors: RET/PTC1
rearrangement in TPC1; heterozygous and homozygous BRAFV600E mutation in K1 and in B-CPAP, respectively. B-
CPAP cells showed a statistically significant (P < 0.01) higher frequency of abnormal mitotic figures compared to
TPC1 and K1 cells.
Conclusions: Our data indicate that RET/PTC1 oncogenic activity is not related to mitotic chromosome impairment
and missegregation whereas, based on the consistent difference in types/frequencies of centrosome and spindle
abnormalities observed between K1 and B-CPAP cells, the hetero/homozygous allelic status of BRAFV600E mutation
seems to be not irrelevant in respect to chromosomal instability development.
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Background
Chromosomal instability (CIN), a genetic condition that
promotes a high rate of chromosome missegregation
during mitosis, is a shared feature of most cancers.
Aneuploidy is a distinctive trait of most human cancers
and has been linked to high tumour grade, advanced
stage, and poor prognosis; however, its role in neoplastic
transformation and the relationship with CIN are some-
what unclear [1]. A variety of alterations have been pro-
posed as being responsible for CIN, including defects in
the spindle checkpoint, defective sister-chromatid cohe-
sion, kinetochore assembly, upregulation of cyclins, ero-
sion of telomeres and centrosome abnormalities [2]. The
normal function and numeral integrity of centrosomes
can be affected directly by the mutated products of cer-
tain proto-oncogenes and tumour-suppressor genes
[3,4]. In particular, centrosome amplification (the pre-
sence in the cell of more than two centrosomes) seems
to be an early event in tumourigenesis [5], and it may
affect CIN in different ways, depending on the capacity
to maintain a correct bipolar chromosome segregation
in the presence of multipolar spindles. In addition to
amplification, structural and functional defects of cen-
trosomes may influence CIN [4].
Papillary thyroid carcinoma (PTC), accounting for
approximately 80% of differentiated thyroid carcinoma
(DTC), has a number of variants with specific histologi-
cal characteristics. The classical form of PTC may show
activation of the BRAF gene or RET/PTC variants, in
40-45% and 10-20% of cases, respectively [6]. The two
alterations are usually mutually exclusive. In different
PTC-derived cell lines, the alternative presence of either
BRAF mutation or RET/PTC rearrangement has been
confirmed [7], reinforcing the hypothesis that RET and
BRAF changes are alternative oncogenic events. The
majority of papillary thyroid carcinoma shows stable
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karyotypes, including the cases in which aneuploid kar-
yotypes have been described [8], being chromosomal
instability only observed in the more advanced clinico-
pathological stages [9]. Intriguingly, however, it has been
demonstrated that conditional BRAFV600E expression
induces chromosomal instability in thyroid PCCL3 cells
[10], suggesting a possible key role of the gene in deter-
mining CIN. Moreover, the contribution of centrosome
in the morphogenetic process of PTC nuclear changes
has been recently suggested [11]. Nevertheless, little is
known about the relationship among PTC molecular
events, aneuploidy and genomic instability of these
tumours.
TPC1, K1 and B-CPAP PTC-derived cell lines are
characterized by the specific genetic alterations of the
parental tumours from which they have been derived,
namely RET/PTC1 rearrangement in TPC1 [12],
BRAFV600E mutation in K1 and in B-CPAP [7]. To
investigate the possible relationship between the relevant
specific gene alterations and mitotic behavior of thyroid
cancer cells, we studied centrosome abnormalities and
mitotic spindle aberrations of these three human PTC-
derived cell lines and of NTHY-ORI3.1 cells derived
from human follicular epithelial cells.
Results
Fluorescence in situ hybridization
RET FISH pattern intepretation. Diploid cells that have
the chromosomal rearrangement involving the RET gene
will show a discrete red signal distanced from a discrete
green signal, indicating the breakage of one RET allele,
while the second allele will show a red/green fused sig-
nal. Depending on chromosome 10 polysomy, this pat-
tern will change accordingly.
NTHY-ORI-3.1 cell line
Nuclei of the NTHY-ORI-3.1 cell line showed two, three
or four red/green intact signals, indicating no RET rear-
rangement and the presence of tri-tetraploid clones, in
addition to the diploid one (Figure 1a).
PTC-derived cell lines
Most nuclei of the TPC1 cell line showed two intact
red/green signals and two red and two green discrete
signals, indicating the presence of RET breakage in the
tetraploid clone (Figure 1b). A minor diploid clone
showed one intact red/green signal and one red and one
green discrete signals. Nuclei of the K1 cell line showed
four intact red/green fluorescent signals, as expected for
tetrasomy 10 (Figure 1c) in a tetraploid cell line. Nuclei
of the B-CPAP cell line showed red/green intact signals.
According to the presence of a major clone with trisomy
10, most of the nuclei showed three intact red/green sig-
nals (Figure 1d).
These results indicated that only TPC1 cells had RET
rearrangement.
Immunofluorescence results
NTHY-ORI-3.1 cell line
A very low frequency of centrosome amplification (0,7%)
and spindle abnormalities (1,7%) were observed in the
control SV-40-immortalized cell line NTHY-ORI-3, as
an effect of SV40 immortalization (Figures 2 and 3).
PTC-derived cell lines
B-CPAP cells displayed a significantly higher (P < 0.01)
frequency of centrosome amplification (21,4%), when
compared to normal thyroid tissue derived NTHY-ORI-
3.1 cell line (0,7%) and the papillary thyroid tumour
derived TPC1 (1,1%) and K1 (1,8%) cell lines (Figure 2).
In detail, NTHY-ORI-3.1 cells showed normal centro-
somes (Figure 4a) as well as TPC1 (Figure 4b) and K1
(Figure 4c) cells, whereas in B-CPAP cells centrosome
amplification was observed (Figure 4d). The
Figure 1 Fluorescence in situ hybridization. FISH with a home-
brew dual color break-apart probe set for RET gene (5’ labelled with
Spectrum Orange and 3’ labeled with Spectrum Green). Cells with
unrearranged RET show intact red/green signals (one fused signal
for each RET gene); cells with rearranged RET show probe signal
split into its 5’ (red signal) and 3’ (green signal) portions (two
discrete red and green signals for each rearranged RET gene). NTHY-
ORI 3-1 representative nuclei with four (a, top) and two (a, bottom)
copies of intact RET; TPC1 representative nucleus with two copies of
intact RET (two red/green signals) and two copies of rearranged RET
(two discrete red and green signals) (b); K1 representative nucleus
with four copies of intact RET (c); B-CPAP repesentative nucleus with
three copies of intact RET (d). Nuclei are counterstained with 4’,6-
diamidino-2-phenylindole.
Maric et al. Molecular Cytogenetics 2011, 4:26
http://www.molecularcytogenetics.org/content/4/1/26
Page 2 of 8
immunofluorescence with anti-centrin 2 antibody
showed one or two centriolar pairs in NTHY-ORI-3.1
(Figure 4e), TPC1 (Figure 4f), and K1 (Figure 4g), and
amplification (centriolar pairs > 2) in B-CPAP (Figure
4h, i).
Among the four analyzed cell lines (Figure 3, Figure
4j-p), only B-CPAP cells showed a statistically significant
(P < 0.01) higher frequency of abnormal mitotic figures
(15.9%) (Figure 4m, n, o) compared to both follicular
cells derived NTHY-ORI-3.1 (1,7%) and tumour derived
TPC1 (0,9%) and K1 (1,8%) cell lines. A small fraction
of B-CPAP cells showed acentrosomal spindle poles
(Figure 4p).
Giemsa-staining results
NTHY-ORI-3.1 cell line
NTHY-ORI-3.1 cells showed a total of 9.2% aberrant
mitotic figures, mainly consisting of metaphases with
misaligned chromosomes (2,8%) and anaphases with
chromosome laggings (5,6%). A very low percentage of
mitosis (0,6%) showed multipolar spindles (Figures 5
and 6).
PTC-derived cell lines
Among the three thyroid cancer derived cell lines, both
TPC1 and K1 cells showed approximately 7% aberrant
mitotic figures (Figures 5 and 6). Most of the TPC1
abnormal mitosis were metaphases with misaligned
chromosomes (Figure 7a) (5,7%) and a minority involved
chromosome laggings (0,5%) and multipolar mitoses
(0,9%). The K1 cells showed metaphases with misaligned
chromosomes (3,8%) or chromosome laggings (2,3%),
and few multipolar mitosis (0,8%). Comparing the
abnormal mitotic figures of these cell lines with those of
Giemsa-stained B-CPAP cells, a statistically significant
(P < 0.01) higher frequency of abnormal mitotic figures
was found in B-CPAP cells (28.3%) (Figures 4 and 5),
including misaligned chromosomes (10,7%) (Figure 7b),
ana-telophase lagging chromosomes (2,0%) (Figure 7c),
multipolar figures (6,8%) (Figure 7d), c-metaphases
(3,8%) (Figure 7e), and other alterations (5%), such as
highly polyploid figures, pulverized metaphases and
others that were difficult to classify (Figure 7f).
Discussion
A number of gene alterations, such as point mutations
in RAS and BRAF genes, point mutations or amplifica-
tion of PIK3CA, and fusion genes involving RET,
NTRK1 and PPARg are known to frequently occur in
differentiated thyroid carcinoma [6,13], and are corre-
lated to different morphological subtypes. Moreover,
they are characterized by different chromosome pat-
terns, defining specific cytogenetic subgroups which are
Figure 2 Centrosome analysis (immunofluorescence).
Distribution of centrosome abnormalities in the studied cell lines:
preponderance of abnormal centrosomes in B-CPAP cells.
Figure 3 Mitotic spindle analysis (immunofluorescence) .
Distribution of spindle mitotic abnormalities in the studied cell lines:
preponderance of metaphase spindle abnormalities in B-CPAP cells.
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often correlated with different histopathological features
[14].
Common mutations found in the papillary histologic
subtype are point mutations of the BRAF and RAS
genes as well as RET/PTC rearrangements, which are
considered molecular markers of diagnostic and prog-
nostic significance.
TPC1, K1, and B-CPAP are among the most fre-
quently used papillary thyroid carcinoma-derived cell
lines for in vitro investigations of thyroid oncogenesis.
Figure 4 Centrosome and mitotic spindle immunofluorescence, representative images. Centrosome g-tubulin immunostaining (green
signal): normal centrosome in NTHY-ORI 3-1 (a), TPC-1 (b) and K1 (c) cell lines; amplified centrosome in B-CPAP cell line (d). Centriol centrin 2
immunostaining (green signal): one pair of centriols in NTHY-ORI 3-1 (e), TPC-1 (f) and K1 (g) cell lines; amplification in B-CPAP cell line: four pairs
(h) and five pairs (i) of centriols. Gamma- and b-tubulin immunostaining highlighting centrosomes (green signal) and mitotic spindle
microtubules (red signal): normal mitotic figures in NTHY-ORI 3-1 (j), TPC-1 (k), and K1 (l) cell lines; abnormal mitotic figures in B-CPAP cell line: a
tripolar metaphase (m), a quadripolar metaphase (n); a multipolar metaphase (o), and a tripolar metaphase with two acentrosomal spindle poles
(p).
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Although tumour derived cell lines are considered to be
the outcome of adaptation and in vitro evolution leading
to a common undifferentiated phenotype [15], all these
cell lines maintained the biologically relevant oncogenic
events specific to the different subtypes of their parental
PTCs. TPC1 and K1 cell lines, bearing RET/PTC1 and
heterozygous BRAFV600E mutation respectively, had an
extremely low number of aberrant cells. No statistically
significant differences were found in centrosome and
spindle alterations, as well as multipolar mitoses, com-
pared to follicular thyroid cell-derived NTHY-ORI-3.1
cell line, which indeed is a SV-40 immortalized cell line
and a population of abnormal mitotic cells can be
expected. In contrast, the B-CPAP cell line, bearing a
homozygous BRAFV600E mutation, showed remarkable
alterations: several mitotic abnormalities such as
metaphase chromosome misalignments, multipolar fig-
ures, and c-metaphases were observed. Intriguingly,
these types of alterations were barely observed in the K1
cell line harbouring heterozygous BRAFV600E mutation.
The consistent difference in types/frequencies of centro-
some and spindle abnormalities observed between K1
and B-CPAP cells might suggest that the allelic status of
BRAFV600E mutation is not irrelevant in respect to CIN
development, and that the hetero/homozygous muta-
tional status of the gene may influence at different rate
the onset of aneuploidy in PTC cells. B-CPAP cells
show a mitotic machinery deeply impaired, withFigure 5 Mitotic figures analysis (Giemsa staining). Distribution
of abnormal mitotic figures in the studied cell lines: preponderance
of abnormal metaphases in B-CPAP cells, and difference of mitotic
alterations between the TPC1 and K1 small abnormal cell
populations (K1 has preponderance of abnormal ana-telophase).
Figure 6 Distribution of abnormal figures during mitotic
phases (Giemsa staining). Overall distribution of different classes
of aberrations during mitosis in the studied cell lines: among the
PTC-derived cell lines, B-CPAP shows the highly consistent number
of mitotic abnormal figures in all phases. Ana-telophase laggings in
NTHY-ORI 3-1 cells are possibly a consequence of SV40-transfection.
Figure 7 Abnormal mitotic figures, Giemsa staining
representative images. TPC1, metaphase displacement (a); B-CPAP,
metaphase displacement (b); B-CPAP, anaphase lagging (c); B-CPAP,
quadripolar metaphase (d); B-CPAP, c-metaphase (e); B-CPAP,
chromosome displacements suggesting the presence of an extra
centrosome: the angle formed by the chromosomes on the right
(arrow) possibly indicates that they are attached to microtubules
from an extra centrosome (f).
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centrosome amplification, acentrosomal spindle poles
and chromosome misalignment, giving rise to an
increased mitotic instability, whereas BRAFV600E hetero-
zygous K1 cells maintain correct centrosome features
and spindle polarity in the majority of cells. In fact, B-
CPAP cell line has a less stable karyotype compared to
K1. Moreover, as expected, because of centrosome ampli-
fication, B-CPAP showed a significantly higher frequency
of multipolar mitoses compared to K1. A small propor-
tion of these mitoses showed acentrosomal spindle poles,
which are reminiscent of spindle formation involving
nucleation through a chromatin-dependent spindle
assembly pathway [16]. Very recently, a link between the
BRAFV600E oncogene and chromosome instability in mel-
anoma has been suggested [17]. More than 65% of cuta-
neous melanoma [18] and approximately 45% of PTC [6]
share the same BRAFV600E mutation, however, differently
from melanoma in which aneuploid karyotypes are fre-
quent [8] and homozygous BRAFV600E mutation is
described [19], PTC usually has heterozygous mutation
[20]. To the best of our knowledge, in vivo homozygous
BRAFV600E mutation in thyroid tumours has not been yet
described, and it is likely that homozygous cell lines have
acquired the second mutation during their establishment.
Nevertheless, as B-CPAP is the only of the three PTC-
derived cell lines harboring a mutation in TP53, which
has been closely related to centrosome duplication and
genomic integrity maintenance [4,21], the possibility that
TP53 mutation could be involved in the observed
enhanced instability, can not be ruled out.
Chromosome number in K1 and TPC1 cell lines is
maintained rather stable in culture. However, K1 cells
karyotype is characterized by both structural and numeri-
cal chromosome changes, whereas TPC1 karyotype is
characterized by structural changes [15]. Indeed, the
small population of K1 cells bearing mitotic abnormal-
ities shows mainly ana-telophase laggings, compared to
the small population of mitotic abnormal TPC1 cells (P <
0.05). As lagging chromosomes at anaphase represent a
potential source of aneuploidy, the presence of this small
abnormal ana-telophase population may explain the pre-
sence of clonal chromosome numerical changes in K1
karyotype. Intriguingly, BRAFV600E positive PTC may
harbour aneuploidy [9], whereas RET/PTC positive carci-
noma very rarely shows numerical chromosome changes
- and indeed RET/PTC rearrangements have been
reported in non-malignant thyreocytes [22]. A direct
ascertainment of the mitotic behavior and centrosome
status of PTC with BRAFV600E mutation in primary PTCs
might favourably confirm this view.
Conclusions
Our data suggest that difference in spindle abnormalities
and possibly in centrosome amplification may depend
on the BRAFV600E heterozygous/homozygous mutational
status. Whether the proneness to accumulate numerical
chromosome changes only in the more rare advanced
forms of PTC might depend on the gain of a second
BRAFV600E mutation, and/or accumulation of other gene
alterations, remains to be clarify.
The degree and type of genetic instability in cancer is
emerging as an important feature, also considered as a
possible ancillary and integrative parameter in tumour
classification. Besides the prognostic relevance of chro-
mosomal instability, CIN could also contribute to the
ability of cancer cells to acquire chemoresistance, gener-
ating occasionally cells with the capacity to grow more
efficiently in adverse environments. In this view, investi-
gation of the correlation between neoplasia gene-specific
mutational status and chromosomal instability could
provide better targets for gene-specific therapies.
Methods
Cell lines
The PTC-derived TPC1 and B-CPAP cell lines were kindly
provided by Dr. Fusco (Medical School, University Feder-
ico II of Naples, Naples, Italy), the PTC-derived K1 cell
line was purchased from Health Protection Agency Cul-
ture Collections [23]. TPC1, K1 and B-CPAP cell lines
were chosen according to their reported molecular and
cytogenetic features: the TPC1 cell line originally showed
a near-diploid karyotype and contains a RET/PTC1 rear-
rangement [7], the B-CPAP cell line has an aneuploid kar-
yotype (chromosome mode 72) [24] and BRAFV600E
homozygous mutation [7], the K1 cell line had a near tet-
raploid karyotype [25] and BRAFV600E heterozygous muta-
tion [7]. We confirmed by FISH that the RET
rearrangement was present only in TPC1 cells. TaqMan
Real-Time polymerase chain reaction assay confirmed the
presence of the BRAFV600E mutation in B-CPAP and K1
cells. Karyotyping revealed tetraploidization of TPC1 (a
phenomenon already reported in this cell line) [25] and
maintenance of the described B-CPAP [23] and K1 [25]
chromosome patterns. K1 cells are also characterized by
PIK3CA amplification [26], which is absent in TPC1, B-
CPAP, and NTHY-ORI 3-1 cell lines. For comparison, a
commercially available [23] NTHY-ORI 3-1 cell line was
used [27]. This SV40-transfected cell line, obtained from
human normal thyreocytes, bears wild-type RET and
BRAF genes and retains some morphologic and physiolo-
gical characteristics of normal thyreocytes, without evi-
dence of malignant transformation [27]. TP53 mutation
was present in B-CPAP [7] cells. All cell lines lack RAS
mutations [7]. The cell lines were maintained in DMEM/
F12 (Sigma-Aldrich, Milan, Italy) [except NTHY-ORI 3-1
that was grown in RPMI 1640 (Gibco-BRL. Life Technolo-
gies, Milan. Italy)] supplemented with 10% fetal bovine
serum (Gibco-BRL), at 37°C in humidified 5% CO2.
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Fluorescence in situ hybridization
To investigate the presence of RET/PTC rearrangement,
double target dual color FISH (i.e. the simultaneous
hybridization of two probe sets labelled with different
fluorophores) was performed using two 3’ and two 5’
bacterial artificial chromosome (BAC) clones flanking
the common RET breakpoint. 5’ BAC clone RP11-
686A03 and RP11-290I03 (CHORI, Oakland, CA, U.S.
A.) were directly labelled with Spectrum Orange fluoro-
phore-conjugated dUTP (Abbott Molecular/Vysis,
Downers Grove, IL) and 3’ BAC clones RP11-818P01
and RP11-696N03 (CHORI), were labelled with Spec-
trum Green (Abbott Molecular/Vysis). 20 ng/μl of each
probe set were simultaneously hybridized on nuclei:
denaturation 5 minutes at 75°C, hybridization 16 h at
37°C in Hybrite™ (Abbott Molecular/Vysis). Slides were
counterstained with antifading solution (200 ng/ml 4’,6-
Diamidino-2-phenylindole, DAPI) (Sigma-Aldrich).
Hybridization signals were evaluated by scoring 200
interphase nuclei for each cell line, using a digital image
analysis system based on an epifluorescence Olympus
BX41 microscope and charge-coupled device camera
(Cohu), interfaced with the CytoVysion system (software
3.93.2 Applied Imaging, Pittsburg, PA, USA). The Spec-
trum Orange, Spectrum Green, and DAPI images were
acquired with selective single-bandpass filters at 1000×
optical magnification.
Immunofluorescence staining
Cells for immunofluorescence were cultured directly on
flaskette glass slides (NUNC A/S, Roskilde, Denmark).
The cells were fixed with methanol:acetone (1:1) for 10
min at -20°C, followed by 10 min methanol at -20°C.
Centrosomes and mitotic spindle were labeled with a
rabbit polyclonal anti-g-tubulin antibody (Sigma-
Aldrich) and with a mouse anti-b-tubulin antibody
(Sigma-Aldrich), respectively. After 1 h incubation with
the antibodies diluted 1:200 in PBS/1% BSA at 37°C and
3 × 5 min washing in PBS, the slides were incubated
with fluorescein isothiocyanate (FITC)-coupled anti-rab-
bit secondary antibody (Sigma-Aldrich) and TRITC-con-
jugated anti-mouse secondary antibody (Sigma-Aldrich)
for 30 min at 37°C. After 3 × 5 min washing in PBS, the
cells were counterstained with DAPI. Centrosome struc-
tural abnormalities were considered to be present when
a diameter of at least twice that of normal centrosomes
in lymphocytes and in NTHY-ORI 3-1 cells was
observed; amplification was recorded when there were
more than two centrosomes per cell [28]. At least 200
consecutive cells per sample were examined. Centrioles
were labeled with a rabbit anti-centrin 2 antibody (dilu-
tion 1:200) (Santa Cruz Biotechnology, Santa Cruz (CA),
USA), applying the same procedure described above.
Preparations were observed using an epifluorescence
microscope (Provis AX70, Olympus, Milan, Italy), and
images were acquired with a digital CCD camera
(C4742 Orca II, Hamamatsu, Japan) driven by Cytovi-
sion (Applied Imaging Corp., Santa Clara, CA, USA).
The DAPI, FITC and TRITC images were acquired with
selective single-bandpass filters at 1000× optical
magnification.
Giemsa staining
The cells grown on slides were washed twice with PBS,
fixed with methanol:acetic acid (3:1) for 30 min at 4°C,
and stained in 4% buffered Giemsa stain (pH 7.2) for 25
min. At least 200 consecutive mitotic figures per sample
were examined by light microscopy, and images were
acquired with a CCD camera at 1000× optical
magnification.
Statistics
Frequency distributions of all variables were calculated,
and chi-square analyses were used for categorical com-
parisons. A p-value < 0.01 was considered statistically
significant.
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